Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression

Authors: Amrendra K Ajay, Ankur K Upadhyay, Sandeep Singh, Maleppillil V Vijayakumar, Ratna Kumari, Vimal Pandey, Ramanamurthy Boppana, Manoj K Bhat

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

p53 is the most studied tumor suppressor and its overexpression may or may not cause cell death depending upon the genetic background of the cells. p53 is degraded by human papillomavirus (HPV) E6 protein in cervical carcinoma. Several stress activated kinases are known to phosphorylate p53 and, among them cyclin dependent kinase 5 (Cdk5) is one of the kinase studied in neuronal cell system. Recently, the involvement of Cdk5 in phosphorylating p53 has been shown in certain cancer types. Phosphorylation at specific serine residues in p53 is essential for it to cause cell growth inhibition. Activation of p53 under non stress conditions is poorly understood. Therefore, the activation of p53 and detection of upstream kinases that phosphorylate non-genotoxically overexpressed p53 will be of therapeutic importance for cancer treatment.

Results

To determine the non-genotoxic effect of p53; Tet-On system was utilized and p53 inducible HPV-positive HeLa cells were developed. p53 overexpression in HPV-positive cells did not induce cell cycle arrest or apoptosis. However, we demonstrate that overexpressed p53 can be activated to upregulate p21 and Bax which causes G2 arrest and apoptosis, by inhibiting protein phosphatase 2A. Additionally, we report that the upstream kinase cyclin dependent kinase 5 interacts with p53 to phosphorylate it at Serine20 and Serine46 residues thereby promoting its recruitment on p21 and bax promoters. Upregulation and translocation of Bax causes apoptosis through intrinsic mitochondrial pathway. Interestingly, overexpressed activated p53 specifically inhibits cell-growth and causes regression in vivo tumor growth as well.

Conclusion

Present study details the mechanism of activation of p53 and puts forth the possibility of p53 gene therapy to work in HPV positive cervical carcinoma.
Appendix
Available only for authorised users
Literature
1.
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989, 244: 217-221. 10.1126/science.2649981CrossRefPubMed
2.
Brown JC, Lain S, Fersht AR, Lane DP: Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer. 2009, 9: 862-873. 10.1038/nrc2763.CrossRef
3.
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991, 253: 49-53. 10.1126/science.1905840CrossRefPubMed
4.
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990, 248: 76-79. 10.1126/science.2157286CrossRefPubMed
5.
Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP: Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene. 2007, 26: 4059-4070. 10.1038/sj.onc.1210188PubMedCentralCrossRefPubMed
6.
Thomas MC, Chiang CM: E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell. 2005, 17: 251-264. 10.1016/j.molcel.2004.12.016CrossRefPubMed
7.
Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F: siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003, 22: 5938-5945. 10.1038/sj.onc.1206894CrossRefPubMed
8.
Mantovani F, Banks L: Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene. 1999, 18: 3309-3315. 10.1038/sj.onc.1202688CrossRefPubMed
9.
Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 1995, 55: 4210-4213.PubMed
10.
Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, Notario V: Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ. 1993, 4: 367-376.PubMed
11.
Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, Mitchell MF: Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996, 56: 3047-3054.PubMed
12.
St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K: Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther. 2000, 7: 749-756. 10.1038/sj.cgt.7700166CrossRefPubMed
13.
Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC: Two posttranscriptional pathways that regulate p21 (Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res. 1999, 247: 168-175. 10.1006/excr.1998.4345CrossRefPubMed
14.
Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F: Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene. 2006, 25: 4009-15. 10.1038/sj.onc.1209429CrossRefPubMed
15.
Gene therapy deserves a fresh chance. Nature editorial. 2009, 461: 1173-
16.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75: 817-825. 10.1016/0092-8674(93)90500-PCrossRefPubMed
17.
Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004, 303: 1010-1014. 10.1126/science.1092734CrossRefPubMed
18.
19.
Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N: Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res. 1999, 5: 1015-1023.PubMed
20.
McCormick F: Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther. 2003, 2: S157-160.CrossRefPubMed
21.
Chhipa RR, Kumari R, Upadhyay AK, Bhat MK: Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. Exp Cell Res. 2007, 313: 3945-3958. 10.1016/j.yexcr.2007.08.022CrossRefPubMed
22.
Upadhyay AK, Singh S, Chhipa RR, Vijayakumar MV, Ajay AK, Bhat MK: Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2. Toxicol Appl Pharmacol. 2006, 216: 177-185. 10.1016/j.taap.2006.05.009CrossRefPubMed
23.
Zhao LY, Liao D: Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol. 2003, 77: 13171-13181. 10.1128/JVI.77.24.13171-13181.2003PubMedCentralCrossRefPubMed
24.
Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA. 1999, 96: 13777-13782. 10.1073/pnas.96.24.13777PubMedCentralCrossRefPubMed
25.
Cohen P, Cohen PT: Protein phosphatases come of age. J Biol Chem. 1989, 264: 21435-21438.PubMed
26.
Yan Y, Mumby MC: Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein. PP2a regulates the activities of G(1) cyclin-dependent kinases. J Biol Chem. 1999, 274: 31917-31924. 10.1074/jbc.274.45.31917CrossRefPubMed
27.
Millward TA, Zolnierowicz S, Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 1999, 24: 186-191. 10.1016/S0968-0004(99)01375-4CrossRefPubMed
28.
Olsson A, Manzl C, Strasser A, Villunger A: How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ. 2007, 14: 1561-1575. 10.1038/sj.cdd.4402196CrossRefPubMed
29.
Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 2007, 8: 275-283. 10.1038/nrm2147CrossRefPubMed
30.
Braun K, Ehemann V, Waldeck W, Pipkorn R, Corban-Wilhelm H, Jenne J, Gissmann L, Debus J: HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). Cancer Lett. 2004, 209: 37-49. 10.1016/j.canlet.2004.02.022CrossRefPubMed
31.
Buxbaum JD, Dudai Y: A quantitative model for the kinetics of cAMP-dependent protein kinase (type II) activity. Long-term activation of the kinase and its possible relevance to learning and memory. J Biol Chem. 1989, 264: 9344-9351.PubMed
32.
Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z: Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA. 2009, 106: 11697-11702. 10.1073/pnas.0905930106PubMedCentralCrossRefPubMed
33.
Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M: Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA. 2001, 98: 1218-1223. 10.1073/pnas.031470698PubMedCentralCrossRefPubMed
34.
Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell. 2004, 116: 205-219. 10.1016/S0092-8674(04)00046-7CrossRefPubMed
35.
Bode AM, Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004, 4: 793-805. 10.1038/nrc1455CrossRefPubMed
36.
Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 1992, 71: 505-514. 10.1016/0092-8674(92)90518-HCrossRefPubMed
37.
Lee JH, Kim HS, Lee SJ, Kim KT: Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci. 2007, 120: 2259-2271. 10.1242/jcs.03468CrossRefPubMed
38.
Goodyear S, Sharma MC: Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp Mol Pathol. 2007, 82: 25-32. 10.1016/j.yexmp.2006.09.002CrossRefPubMed
39.
Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD: Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 2006, 66: 7509-7515. 10.1158/0008-5472.CAN-05-3048CrossRefPubMed
40.
Upadhyay AK, Ajay AK, Singh S, Bhat MK: Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets. 2008, 8: 741-752. 10.2174/156800908786733405CrossRefPubMed
41.
Tsai LH, Delalle I, Caviness VS, Chae T, Harlow E: p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994, 371: 419-423. 10.1038/371419a0CrossRefPubMed
42.
D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002, 4: 11-19. 10.1038/ncb714CrossRefPubMed
43.
Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, Müller H, Helin K: Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001, 3: 552-558. 10.1038/35078527CrossRefPubMed
Metadata
Title
Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression
Authors
Amrendra K Ajay
Ankur K Upadhyay
Sandeep Singh
Maleppillil V Vijayakumar
Ratna Kumari
Vimal Pandey
Ramanamurthy Boppana
Manoj K Bhat
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-204

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

An essential role for Ran GTPase in epithelial ovarian cancer cell survival

Research

LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications

Research

Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells

Research

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

Research

Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model

Research

Tumor promoting effects of CD95 signaling in chemoresistant cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits